Holen Sie sich die Stockscreener-App
85.86
20.13%
-21.64
Handel nachbörslich:
87.00
1.14
+1.33%
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
In a trial, 24% of patients with hard-to-control type 2 diabetes had excess cortisol. - Stock Titan
Corcept Therapeutics Incorporated Announces ADA/EASD Consensus Report Cites CATALYST Trial On Mifepristone For Hypercortisolism In Difficult-To-Control Type 2 Diabetes - www.marketscreener.com
2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes - Yahoo Finance
Piper Sandler Reaffirms Their Buy Rating on Corcept Therapeutics (CORT) - The Globe and Mail
The Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics - Zacks Investment Research
The Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics - The Globe and Mail
Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym? - Zacks Investment Research
Can Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym? - Yahoo Finance
The Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics - Zacks Investment Research
Corcept Therapeutics Incorporat (CORT) Stock forecasts - Yahoo Finance Australia
Corcept Therapeutics director Wilson sells $1.15 million in shares - Investing.com
Corcept Therapeutics Director James N. Wilson Sells 10,000 Shares on October 15 Under 10b5-1 Plan - Kalkine Media
A director's trust sells 10,000 shares under a trading plan at Corcept Therapeutics (CORT). - Stock Titan
Corcept Therapeutics Incorporat (CORT) Stock Forecasts - Yahoo Finance
Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains - Zacks Investment Research
3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge - Zacks Investment Research
Corcept Therapeutics Incorporat (CORT) Stock forecasts - Yahoo Finance UK
FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer - Zacks Investment Research
Here's Why You Should Add EYPT Stock to Your Portfolio Now - Zacks Investment Research
RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week - Zacks Investment Research
Corcept Therapeutics Incorporat (CORT) Stock Forecasts - Yahoo Finance
Corcept Therapeutics (CORT) Stock Looks Fully Priced For Its Sales Story - Yahoo Finance
Corcept Therapeutics (CORT) Draws Options Attention, Is It Still 18% Below Fair Value? - Yahoo Finance
Corcept Therapeutics Incorporat (CORT) Stock Forecasts - Yahoo! Finance Canada
LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label - Zacks Investment Research
Does Elevated Put Options Activity Change The Bull Case For Corcept Therapeutics Stock (CORT)? - Simply Wall Street
Here's Why You Should Add ANRO Stock to Your Portfolio Now - Zacks Investment Research
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal - Zacks Investment Research
BMY Reports Mixed Phase III Trial Results, Stock Down - Zacks Investment Research
Are Options Traders Betting on a Big Move in Corcept Therapeutics Stock? - Zacks Investment Research
Are Options Traders Betting on a Big Move in Corcept Therapeutics Stock? - Yahoo Finance
Drugmaker Corcept seeks to bar ex-judge's views in Teva antitrust case - Reuters
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why - Zacks Investment Research
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know - Zacks Investment Research
Corcept Therapeutics Inc (HTD.DU) Stock Forum & Discussion - Yahoo! Finance Canada
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Erasca, Inc. (ERAS), DICK’S Sporting Goods, Inc. (DKS), Corcept Therapeutics Incorporated (CORT), and Charter Communications, Inc. (CHTR) - Supply Chain Digital
Piper Sandler Keeps Their Buy Rating on Corcept Therapeutics (CORT) - The Globe and Mail
Corcept Therapeutics Incorporat (CORT) Stock Forecasts - Yahoo Finance
Corcept Therapeutics Insider Sold Shares Worth $2,906,601, According to a Recent SEC Filing - Yahoo Finance
Corcept Therapeutics (NasdaqCM:CORT) Stock Forecast & Analyst Predictions - Simply Wall Street
Corcept Therapeutics Insider Sold Shares Worth $1,160,731, According to a Recent SEC Filing - Yahoo Finance
Form 4 Corcept Therapeutics Incorporated For: 5 October By Investing.com - Investing.com India
Form 4 Corcept Therapeutics Incorporated For: 5 October By Investing.com - Investing.com Nigeria
Corcept Therapeutics president Sean Maduck sells $2.9 million in stock By Investing.com - Investing.com Australia
Corcept Therapeutics president Sean Maduck sells $2.9 million in stock - Investing.com
Corcept Therapeutics president sells $967k in shares - Investing.com
Corcept Therapeutics chief accounting officer sells $1.16m - Investing.com
Corcept Therapeutics Oncology President Reports Stock Option Exercise and Sales in Form 4 Filing - Kalkine Media
Corcept Therapeutics' Sean Maduck Executes Stock Option Exercises and Sells Shares Under 10b5-1 Plan - Kalkine Media
100,000 stock options awarded to Corcept (CORT) officer vest over four years, subject to continued service. - Stock Titan
2.70%
0.91%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):